Watson Pharma (WPI) Confirms Patent Challenges on LUMIGAN, LATISSE

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed Abbreviated New Drug Applications (ANDAs) with the U.S. FDA seeking approval to market Bimatoprost Ophthalmic Solution, 0.01% and Bimatoprost Ophthalmic Solution, 0.03%. Watson's ANDA products are generic versions of Allergan, Inc.'s LUMIGAN® 0.01% and LATISSE® products, respectively. LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LATISSE® is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness and darkness.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial
• NIO delivers 35,836 vehicles in August, up 14.5% year-over-year
• IHT converts $3M debt to equity to meet NYSE American listing rules